Skip to main content
See details

Reimbursement summary for angioplasty of arteries of lower extremities

This post presents an extract from our reimbursement analysis for angioplasty of arteries lower extremities using plain and drug-coated balloons (DCBs) for peripheral artery disease in England, France and Germany. Plain balloon angioplasty is reimbursement via DRG solely and DCBs are reimbursement via combination of DRG and add-on reimbursement.
See details

Two Med Tech mini-HTAs were initiated in Norway in October of 2018

The framework for the introduction of innovations into the health care system through either a national or hospital-based health technology assessment was established in Norway in 2013. This framework is called the “New Method”.

In this framework, all innovations should undergo HTA before being funded. If the method concerns only one or two hospitals, assessment shall be initiated by clinicians and ran at the hospital level. The final report is disseminated via a mini-HTA database. If the method is of national concern, it undergoes Single Technology Appraisal at national level followed by the funding decision by the group of payers (Decision Forum, Beslutningsforum).

In October of 2018, two mini-method assessments were initiated:

  • The magnetic technology (Magseed) for labeling non-palpable breast lesions by Health Bergen;
  • Robotic-assisted minimally invasive harvesting of muscle patches for reconstructive surgery by Oslo University Hospital.

All finalized mini-method assessments will be published in the National Database for Mini-Method Assessments.

See the full details in Norwegian here.

Subscribe to our newsletter delivered every second week not to miss important reimbursement information.